Related Experiment Videos
Rapid carcinogenicity testing system with transgenic mice harboring human prototype c-HRAS gene
S Yamamoto1, Y Hayashi, K Mitsumori
1Department of Pharmacology, School of Medicine, Keio University, Tokyo, Japan.
Laboratory Animal Science
|April 1, 1997
Summary
Transgenic (Tg) CB6F1-HRAS2 mice show increased susceptibility to genotoxic carcinogens. These mice demonstrate a promising potential for developing a rapid carcinogenicity testing system due to faster tumor development and higher incidence.
Area of Science:
- Toxicology
- Genetics
- Animal Models
Background:
- Carcinogenicity testing is crucial for drug safety and environmental hazard assessment.
- Existing methods can be time-consuming and resource-intensive.
- Transgenic mouse models offer potential for accelerated testing.
Purpose of the Study:
- To evaluate the CB6F1-HRAS2 transgenic mouse as a model for rapid carcinogenicity testing.
- To assess the susceptibility of CB6F1-HRAS2 mice to genotoxic carcinogens.
- To determine the potential for faster tumor onset and higher incidence in this model.
Main Methods:
- Utilized transgenic (Tg) CB6F1-HRAS2 mice carrying a human prototype c-HRAS gene.
- Conducted short-term tests using various genotoxic carcinogens.
- Compared tumor incidence and onset in Tg mice versus control non-Tg mice.
Main Results:
- CB6F1-HRAS2 mice exhibited higher susceptibility to genotoxic carcinogens compared to control mice.
- Treatment with genotoxic carcinogens led to a more rapid onset of tumors.
- A higher incidence of more malignant tumors was observed in the transgenic model.
Conclusions:
- The CB6F1-HRAS2 mouse model shows promise for rapid carcinogenicity testing.
- This model may allow for quicker and more sensitive detection of carcinogenic potential.
- Further development could lead to a more efficient system for evaluating chemical safety.